-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – NPC-21 in Cytomegalovirus (HHV-5) Infections
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data.NPC-21 in Cytomegalovirus (HHV-5) InfectionsDrug Details:NPC-21 is under development for the treatment of cytomegalovirus infection in...
-
Analyst Opinions
NewGame on – Navigating Future-Play in Gaming
Gaming Startups Overview From the explosion of mobile gaming to the transformative power of cloud-based experiences, the gaming industry is becoming more interconnected and immersive. Advanced technologies are adding new dimensions, leading to innovations like AI-driven game testing, ultra-realistic non-player characters (NPCs), and blockchain-powered play-to-earn games. GlobalData's Startup Series report, titled "Game on: navigating future-play in gaming,"Â offers a comprehensive overview of how innovative gaming startups are driving the change across eight emerging trends and their sub-trends within the gaming world....
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – TED-N in Paralysis
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalDatas proprietary machine learning algorithms developed using over 10 years of historical data.TED-N in Paralysis Drug Details:Stem cell therapy is under development for the treatment of sub-acute spinal...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Ensituximab in Metastatic Pancreatic Cancer
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalDatas proprietary machine learning algorithms developed using over 10 years of historical data.Ensituximab in Metastatic Pancreatic Cancer Drug Details:Ensituximab (NPC-1C, NEO-101, NEO-102) is under development for the treatment...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Seliciclib in Rheumatoid Arthritis
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Seliciclib in Rheumatoid Arthritis Drug Details: Seliciclib (CYC-202) is under development for the treatment...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – TED-N in Acute Spinal Cord Injury
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data.TED-N in Acute Spinal Cord InjuryDrug Details:Stem cell therapy is under development for the treatment of...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Stem Cell Therapy For Epilepsy, Parkinson’S Disease And Spinocerebellar Ataxias in Parkinson’s Disease
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data.Stem Cell Therapy For Epilepsy, Parkinson’S Disease And Spinocerebellar Ataxias in Parkinson's DiseaseDrug Details:Stem cell therapy...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – BGBA-445 in Nasopharyngeal Cancer
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. BGBA-445 in Nasopharyngeal Cancer Drug Details: BGBA-445 is under development for the treatment of...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – BGBA-445 in Melanoma
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. BGBA-445 in Melanoma Drug Details: BGBA-445 is under development for the treatment of advanced,...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – BGBA-445 in Bladder Cancer
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. BGBA-445 in Bladder Cancer Drug Details: BGBA-445 is under development for the treatment of...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – BGBA-445 in Renal Cell Carcinoma
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. BGBA-445 in Renal Cell Carcinoma Drug Details: BGBA-445 is under development for the treatment...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – BGBA-445 in Metastatic Transitional (Urothelial) Tract Cancer
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. BGBA-445 in Metastatic Transitional (Urothelial) Tract Cancer Drug Details: BGBA-445 is under development for...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – BGBA-445 in Non-Small Cell Lung Cancer
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. BGBA-445 in Non-Small Cell Lung Cancer Drug Details: BGBA-445 is under development for the...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – BGBA-445 in Recurrent Head And Neck Cancer Squamous Cell Carcinoma
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. BGBA-445 in Recurrent Head And Neck Cancer Squamous Cell Carcinoma Drug Details: BGBA-445 is...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – BGBA-445 in Solid Tumor
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. BGBA-445 in Solid Tumor Drug Details: BGBA-445 is under development for the treatment of...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Bintrafusp Alfa in Bladder Cancer
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Bintrafusp Alfa in Bladder Cancer Drug Details: Bintrafusp alfa is under development for the treatment...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Bintrafusp Alfa in Urinary Tract Cancer
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Bintrafusp Alfa in Urinary Tract Cancer Drug Details: Bintrafusp alfa is under development for the...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Famitinib in Triple-Negative Breast Cancer (TNBC)
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data.Famitinib in Triple-Negative Breast Cancer (TNBC)Drug Details:Famitinib (SHR-1020) is under development for the treatment of solid...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Famitinib in Human Epidermal Growth Factor Receptor 2 Negative Breast Cancer (HER2- Breast Cancer)
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalDatas proprietary machine learning algorithms developed using over 10 years of historical data.Famitinib in Human Epidermal Growth Factor Receptor 2 Negative Breast Cancer (HER2- Breast Cancer) Drug Details:Famitinib...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Famitinib in Bile Duct Cancer (Cholangiocarcinoma)
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalDatas proprietary machine learning algorithms developed using over 10 years of historical data.Famitinib in Bile Duct Cancer (Cholangiocarcinoma) Drug Details:Famitinib (SHR-1020) is under development for the treatment of...
Sign up to receive regular alerts for our latest analysis and reports. No matter your industry focus, you can keep your finger on the pulse with our timely updates.